Literature DB >> 23729267

Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.

Emre Koca1, Taha Y Kuzan, Omer Dizdar, Taner Babacan, Ilyas Sahin, Erhan Ararat, Kadri Altundag.   

Abstract

Breast cancers with 10 or more positive lymph nodes at the time of diagnosis are staged as pathological N3a (pN3a) and they have poor prognosis. Recent studies showed five-year disease-free survival (DFS) and overall survival (OS) rates of N3a disease as 43-66 and 58-81 %, respectively. We herein present outcomes of our patients with stage pN3a breast cancer. Among 2,578 patients diagnosed with invasive breast carcinoma at Hacettepe University Hospital between 2002 and 2012, 218 patients (8.4 %) had pN3a disease and were included and analyzed retrospectively in this study. Patients with internal mammary, infraclavicular, and supraclavicular node metastasis or distant metastasis at initial diagnosis were excluded. Demographic features, tumor characteristics, treatment regimens, and patient outcomes in terms of DFS and OS were analyzed. Lymph node ratio was defined as the ratio of positive to total removed lymph nodes. The median age was 49. Most common histological subtype was ductal carcinoma (82.1 %). About 82.6 % of patients had stage T2/T3 cancers and 47.7 % (104) had grade III cancers. Estrogen and progesterone receptors were positive in 133 (61 %) and 121 (55.5 %) patients, respectively. HER2 status was known for 213 patients and was positive in 87 (39.9 %) patients. A total of 27 (12.6 %) patients had triple-negative tumors. Lymphovascular invasion, extracapsular extension, and perineural invasion were present in 106 (48.6 %), 105 (48.2 %), 20 (9.2 %) cases, respectively. A total of 18 patients (8.3 %) received neoadjuvant and 200 patients (91.7 %) received adjuvant chemotherapy, mostly with anthracycline- (95 %) and taxane (60 %)-containing regimens. A total of 210 patients (96.3 %) received radiotherapy. Median follow-up was 39.5 months. A total of 96 patients relapsed on follow-up and 64 patients died. Nineteen of the relapses were locoregional and 77 were distant relapses. The 5-year DFS rate was 46.2 % and the OS rate was 69.8 %. In multivariate Cox regression analysis, grade III disease (HR 1.899, 95 % CI 1.196-3.017, P = 0.007), perineural invasion (HR 2.519, 95 % CI 1.341-4.731, P = 0.004), and lymph node ratio (≥ 0.9 vs. <0.9) (HR 2.290, 95 % CI 1.368-3.835, P = 0.002) were significantly associated with DFS, and grade III disease (HR 2.679, 95 % CI 1.500-4.782, P = 0.001) and lymph node ratio (≥ 0.9 vs. <0.9) (HR 2.182, 95 % CI 1.211-3.932, P = 0.009) were significantly associated with OS. Patients with pN3a disease in our cohort have comparable survival rates with other reports in the literature. Within this high risk group of patients, those with grade III disease, perineural invasion, and lymph node ratio ≥ 0.9 seem to confer poorer prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23729267     DOI: 10.1007/s12032-013-0615-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

Review 1.  Prognostic value of nodal ratios in node-positive breast cancer.

Authors:  Wendy A Woodward; Vincent Vinh-Hung; Naoto T Ueno; Yee Chung Cheng; Melanie Royce; Patricia Tai; Georges Vlastos; Anne Marie Wallace; Gabriel N Hortobagyi; Yago Nieto
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

2.  Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients.

Authors:  Suzanne C Schiffman; Kelly M McMasters; Charles R Scoggins; Robert C Martin; Anees B Chagpar
Journal:  J Am Coll Surg       Date:  2011-05-20       Impact factor: 6.113

3.  Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF.

Authors:  C Schmoor; W Sauerbrei; G Bastert; H Bojar; M Schumacher
Journal:  Eur J Cancer       Date:  2001-06       Impact factor: 9.162

4.  Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes.

Authors:  Jun Sang Lee; Seung Il Kim; So Young Choi; Hyung Seok Park; Jong Seok Lee; Seho Park; Jaseung Koo; Byeong-Woo Park; Kyong Sik Lee
Journal:  Int J Clin Oncol       Date:  2011-03-01       Impact factor: 3.402

5.  Significance of pathological evaluation for lymphatic vessel invasion in invasive breast cancer.

Authors:  Masahiro Ito; Takuya Moriya; Takanori Ishida; Shin Usami; Atsuko Kasajima; Hironobu Sasano; Noriaki Ohuchi
Journal:  Breast Cancer       Date:  2007       Impact factor: 4.239

6.  The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.

Authors:  Chen Qiu; Wei Dong; Benhua Su; Qi Liu; Jiajun Du
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

7.  Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer.

Authors:  Sebastian F Schoppmann; Guenther Bayer; Klaus Aumayr; Susanne Taucher; Silvana Geleff; Margaretha Rudas; Ernst Kubista; Hubert Hausmaninger; Hellmut Samonigg; Michael Gnant; Raimund Jakesz; Reinhard Horvat
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

8.  Is there any prognostically different subgroup among patients with stage IIIC (any TN3M0) breast carcinoma?

Authors:  Nüvit Duraker; Zeynep C Caynak; Bakir Bati
Journal:  Ann Surg Oncol       Date:  2007-10-03       Impact factor: 5.344

9.  Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

Authors:  Andrew G Glass; James V Lacey; J Daniel Carreon; Robert N Hoover
Journal:  J Natl Cancer Inst       Date:  2007-07-24       Impact factor: 13.506

10.  Impact of lymph node ratio on survival in papillary thyroid cancer.

Authors:  David F Schneider; Herbert Chen; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2012-12-23       Impact factor: 5.344

View more
  8 in total

1.  Prognostic Factors in Operated Stage IIIC, Pathological N3a Breast Cancer Patients.

Authors:  Ibrahim Turker; Ulku Y Arslan; Ozan Yazici; Ummugul Uyeturk; Berna Oksuzoglu; Burcin Budakoglu; Nuriye Özdemir; Ozlem U Sonmez; Kaan Helvaci; Onur Esbah; Oznur Bal; Ahmet S Ekinci; Nurullah Zengin
Journal:  Breast Care (Basel)       Date:  2014-12       Impact factor: 2.860

2.  Clinical Outcomes of N3 Breast Cancer: A Real-World Study of a Single Institution and the US Surveillance, Epidemiology, and End Results (SEER) Database.

Authors:  Xiang Ai; Xin Liao; Junyan Li; Peng Tang; Jun Jiang
Journal:  Cancer Manag Res       Date:  2020-07-02       Impact factor: 3.989

3.  Association between well-known histopathological criteria and overall survival in invasive ductal carcinoma.

Authors:  Aysenur Deger; Filiz Ozyigit; Ozlem Arik; Fatih Ekici; Ahmet Cinkaya; Mahir Tayfur; Hakki Deger
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers.

Authors:  Min Yao; Elaine Yu; Vincent Staggs; Fang Fan; Nikki Cheng
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

5.  Risk factors for locoregional recurrence after postmastectomy radiotherapy in breast cancer patients with four or more positive axillary lymph nodes.

Authors:  Q Li; S Wu; J Zhou; J Sun; F Li; Q Lin; X Guan; H Lin; Z He
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

6.  Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.

Authors:  An Zou; Diana Lambert; Henry Yeh; Ken Yasukawa; Fariba Behbod; Fang Fan; Nikki Cheng
Journal:  BMC Cancer       Date:  2014-10-24       Impact factor: 4.430

7.  Nontherapeutic Risk Factors of Different Grouped Stage IIIC Breast Cancer Patients' Mortality: A Study of the US Surveillance, Epidemiology, and End Results Database.

Authors:  Yue Qiu; Hongye Chen; Yongjing Dai; Baoshi Bao; Lin Tian; Yuhui Chen
Journal:  Breast J       Date:  2022-08-30       Impact factor: 2.269

8.  Keystone Perforator Island Flap for Postmastectomy Defect Resurfacing in Late-stage Breast Cancer Patients.

Authors:  Irena Sakura Rini; Made Ananda Krisna; Jenisa Kamayana; Kasih Rahardjo Djarot; Alberta Jesslyn Gunardi
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.